Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Neurocrine Bioscienc
(NQ:
NBIX
)
127.06
-1.37 (-1.07%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Neurocrine Bioscienc
< Previous
1
2
3
4
5
6
7
8
9
Next >
NASDAQ:NBIX: a strong growth stock preparing for the next leg up?.
September 27, 2023
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX): a strong growth stock preparing for the next leg up?.
Via
Chartmill
NASDAQ:NBIX qualifies as a high growth stock and is consolidating.
September 26, 2023
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—A High-Growth Stock Gearing Up for Its Next Upward Move.
Via
Chartmill
Why NASDAQ:NBIX Is a Promising High-Growth Stock in the Midst of Consolidation.
September 22, 2023
Why NEUROCRINE BIOSCIENCES INC ( NASDAQ:NBIX ) Is a Promising High-Growth Stock in the Midst of Consolidation.
Via
Chartmill
Analyst Expectations for Neurocrine Biosciences's Future
September 13, 2023
Via
Benzinga
GoDaddy To Rally Around 44%? Here Are 10 Other Analyst Forecasts For Wednesday
September 13, 2023
Needham cut the price target for Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) from $60 to $53. Needham analyst Gil Blum maintained a Buy rating. Rocket Pharmaceuticals shares rose 24.3% to $19.00 in...
Via
Benzinga
Analyst Ratings for Neurocrine Biosciences
August 21, 2023
Via
Benzinga
Analyst Ratings for Neurocrine Biosciences
August 02, 2023
Via
Benzinga
Earnings Outlook For Neurocrine Biosciences
July 31, 2023
Via
Benzinga
What To Know About BMO Capital's Upgrade of Neurocrine Biosciences
July 06, 2023
Via
Benzinga
What's Going On With Neurocrine Biosciences Stock Today?
September 12, 2023
Neurocrine Biosciences Inc (NASDAQ: NBIX) announced positive topline data from the Phase 3 CAHtalyst Adult Study evaluating crinecerfont in adults with classic congenital adrenal hyperplasia (CAH) due...
Via
Benzinga
Can Neurocrine Erase Its Recent Setbacks With This Jump To An Eight-Month High?
September 12, 2023
The company is working on a treatment for a disorder than can cause children to begin puberty early.
Via
Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
September 08, 2023
Via
Benzinga
FDA Greenlights Expanded Use Of Neurocrine Biosciences' Ingrezza: Analysts Weigh In Depression Warning
August 21, 2023
The FDA approved Neurocrine Biosciences Inc's (NASDAQ: NBIX) Ingrezza (valbenazine) capsules for the treatment of adults with chorea associated
Via
Benzinga
Exposures
Product Safety
Confidence Boost From Ingrezza Sales: Analyst Upgrades Neurocrine Biosciences
July 06, 2023
BMO Capital Markets has upgraded Neurocrine Biosciences Inc (NASDAQ: NBIX) from Underperform to Market Perform, with a price target of $96,
Via
Benzinga
Expert Ratings for Neurocrine Biosciences
June 30, 2023
Via
Benzinga
What 15 Analyst Ratings Have To Say About Neurocrine Biosciences
June 05, 2023
Via
Benzinga
Neurocrine Biosciences's Return On Capital Employed Overview
May 08, 2023
Via
Benzinga
Neurocrine Biosciences Clocks 35% Revenue Growth In Q1, Misses On Bottom-Line Performance
May 03, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2023
July 06, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023
May 04, 2023
Via
Benzinga
Neurocrine Biosciences: Q1 Earnings Insights
May 03, 2023
Via
Benzinga
Neurocrine Biosciences's Earnings: A Preview
May 02, 2023
Via
Benzinga
What 15 Analyst Ratings Have To Say About Neurocrine Biosciences
April 17, 2023
Via
Benzinga
3 Pharma Stocks That Could See a Surge in Demand in 2023
April 24, 2023
These pharma stocks to buy are poised for long-term growth in the trillion-dollar biotechnology space, offering tremendous upside ahead
Via
InvestorPlace
Expert Ratings for Neurocrine Biosciences
March 30, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023
March 30, 2023
Via
Benzinga
3 Growth Stocks That Could Disrupt the Healthcare Industry
March 13, 2023
These healthcare growth stocks will continue to provide steady and consistent returns, rewarding smart investors over time.
Via
InvestorPlace
Analyst Expectations for Neurocrine Biosciences's Future
March 03, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2023
March 03, 2023
Via
Benzinga
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
February 14, 2023
From
Sentia Medical Sciences, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.